Mehmet Bilen, MD
Hematology & Oncology · Atlanta, GANPI 1598085193
Payments from drug & device makers
Across 1,037 payments — averaging $20,963 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$8.1M
- Pfizer$4.9M
- Amgen$2.7M
- Exelixis Inc.$1.3M
- Seagen Inc.$1.1M
- Janssen Research & Development, LLC$1.1M
- plus $2.6M from 21 others
Across 9 payments — averaging $916.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$8K
- Astellas Pharma Global Development$171
What the payments were for
- Consulting fees$117,11578%
- Speaking & faculty fees$22,44615%
- Travel & lodging$3,4972%
- Food & beverage$2,8782%
- Education$4,3943%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 61 | $8,139,620 |
| Pfizer | 181 | $4,873,720 |
| Amgen | 28 | $2,719,750 |
| Exelixis Inc. | 49 | $1,274,650 |
| Seagen Inc. | 80 | $1,087,077 |
| Janssen Research & Development, LLC | 96 | $1,079,805 |
| Eisai Inc. | 181 | $744,392 |
| Genentech, Inc. | 25 | $528,001 |
| Astellas Pharma Global Development | 7 | $380,975 |
| Bayer | 48 | $223,891 |
| Incyte Corporation | 187 | $215,473 |
| Eli Lilly | 4 | $154,246 |
| Astrazeneca UK Limited | 4 | $119,411 |
| Ferring Pharmaceuticals Inc. | 3 | $45,137 |
| EMD Serono, Inc. | 25 | $39,307 |
| AstraZeneca | 11 | $36,527 |
| Janssen Scientific Affairs, LLC | 14 | $32,935 |
| E.r. Squibb & Sons, L.L.C. | 7 | $23,556 |
| Sanofi | 10 | $7,844 |
| Macrogenics, Inc. | 1 | $5,610 |
| Johnson & Johnson | 8 | $4,308 |
| GSK | 1 | $1,600 |
| Medivation LLC. | 2 | $910 |
| AVEO Pharmaceuticals, Inc. | 1 | $103 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Genentech USA, Inc. | 1 | $61 |
| Astellas Pharma US Inc | 1 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,739,054 in reported general payments places this provider in the 95th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 129 | $2,897,758 |
| InlytaAxitinib | 79 | $1,248,175 |
| XtandiEnzalutamide | 89 | $1,120,645 |
| ErleadaApalutamide | 56 | $773,118 |
| NubeqaDarolutamide | 54 | $601,754 |
| LenvimaLenvatinib Mesylate | 19 | $426,583 |
| OrgovyxRelugolix | 130 | $338,819 |
| WeliregBelzutifan | 14 | $256,007 |
| Abiraterone Acetate | 175 | $160,104 |
| Sunitinib Malate | 11 | $19,968 |
| EliquisApixaban | 17 | $16,245 |
| XareltoRivaroxaban | 16 | $8,930 |
| Prednisone | 228 | $825 |
| Ondansetron Hcl | 42 | $752 |
| Levothyroxine Sodium | 73 | $562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $1,274,650 | $2,897,758129 claims |
| PfizerInlyta, Eliquis | $4,873,720 | $1,264,42096 claims |
| Astellas Pharma US IncXtandi | $45 | $1,120,64589 claims |
| Johnson & JohnsonErleada, Xarelto | $4,308 | $782,04872 claims |
| BayerNubeqa | $223,891 | $601,75454 claims |
| Eisai Inc.Lenvima | $744,392 | $426,58319 claims |
| MerckWelireg | $8,139,620 | $256,00714 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $32,935 | $160,104175 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Atlanta
- Ajay NookaAtlanta$19.3M
- Olatunji AleseAtlanta$15.5M
- Jonathon CohenAtlanta$8.7M
- Ticiana LealAtlanta$6.1M
- Conor SteuerAtlanta$4.4M
- Anthony HunterAtlanta$4.3M
- Robert BrownAtlanta$4.2M
- Rodolfo BordoniAtlanta$4M
- Kristie BlumAtlanta$3.7M
- Zachariah DefilippAtlanta$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.